section name header

Pronunciation ⬇

doe-FET-il-ide

Classifications ⬆ ⬇

Therapeutic Classification: antiarrhythmics (class III)

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Blocks cardiac ion channels responsible for transport of potassium.
  • Increases monophasic action potential duration.
  • Increases effective refractory period.
Therapeutic effects:
  • Prevention of recurrent AF/AFl.
  • Conversion of AF/AFl to normal sinus rhythm.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed (>90%) following oral administration.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP3A4 isoenzyme; 80% excreted by kidneys via cationic renal secretion, mostly as unchanged drug; 20% excreted as inactive metabolites.

Half-Life: 10 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POwithin hrs2–3 hr‡12–24 hr



‡Steady state levels are achieved after 2–3 days.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: chest pain, QT interval prolongation, TORSADES DE POINTES

Neuro: dizziness, headache

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Tikosyn

Code ⬆

NDC Code